The compound 1-(2,5-dihidroxyphenyl)-(3-pyridine-2-yl)-propenon calchone compound is a derivative that is substituted by two hydroxy groups on the A ring and has a 2-pyridyl group on the ring B. The analysis showed that the compound disconnection this can be synthesized from the starting material 2,5- dihidroxyacetophenon and pyridine-2-carbaldehid. Synthesis of the compound 1- (2,5-dihidroxyphenyl)-(3-pyridine-2-yl)-propenon using microwave method performed by reacting the compound pyridine-2-carbaldehid and 2,5- dihidroxyacetophenon without solvent with a catalyst K2CO3 in microwave. This research aims to study the pharmacodynamic effects of the compound 1-(2,5- dihidroxyphenyl)-(3-pyridine-2-yl)-propenon against acetylcholine receptors that induced in the isolated guinea pig uterine. The compound 1- (2,5- dihidroxyphenyl) - (3-pyridine-2-yl) -propenon given at a dose of 10 μM and 20 μM. Then, agonis given the rate series 10-8 – 10-2 M. In vitro tests have also examined the type of antagonism of the compound 1-(2,5-dihidroxyphenyl)-(3- pyridine-2-yl)-propenon and nature reversibility‟s receptor. In addition to in vitro assays, in this study also tested in silico using a docking program Autodock. The results showed that the compound 1-(2,5-dihidroxyphenyl)-(3-pyridine- 2-yl)-propenon can inhibit uterine smooth muscle contraction induced isolated acetylkolin. In receptors ACh-M3 shifts the value of pD2 significant (p <0.05) only in the group of compounds 1-(2,5-dihidroxyphenyl)-(3-pyridine-2-yl) - propenon 20μM. Value pD2 control group, the compound 1-(2,5- dihidroxyphenyl)-(3-pyridine-2-yl)-propenon 10 μM and 20 μM respectively of 6.13; 5.54 and 5.49. From the analysis of Schild-plot known type of antagonism is competitive (slope: 0.853, pA2: 1,728). Bonding compound 1-(2,5- dihidroxyphenyl)-(3-pyridine-2-yl)-propenon to the ACh-M3 receptors are weaker than the native ligand (tiotropium, docking score: -115.107). The conclusion of this study is the compound 1-(2,5-dihidroxyphenyl)-(3-pyridine-2-yl)-propenon have a competitive antagonist activity at the receptor ACh-M3